Processa Pharmaceuticals, Inc. ((PCSA)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Processa Pharmaceuticals, Inc. is conducting a Phase 2 clinical study titled A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer. The study aims to evaluate the efficacy and safety of the combination of PCS6422 and capecitabine compared to capecitabine alone in patients with advanced or metastatic breast cancer who have limited treatment options.
The study tests two experimental regimens involving PCS6422 and capecitabine, an oral chemotherapy drug, against the standard dose of capecitabine. PCS6422 is an experimental drug designed to enhance the immune response when combined with capecitabine.
This interventional study is randomized with a parallel assignment model and is open-label, meaning no masking is involved. The primary purpose is to assess treatment efficacy.
The study began recruiting on August 21, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on June 18, 2025, indicating ongoing recruitment and study progress.
The outcome of this study could significantly impact Processa Pharmaceuticals’ stock performance by potentially expanding treatment options for breast cancer, a competitive field with several major players. Investors should watch for updates as positive results could enhance market confidence and drive stock value.
The study is ongoing, with further details available on the ClinicalTrials portal.